Evidence map›Paper›PMID 25927630›Full record

ArticleBMC medical genetics2015

Impact of PTBP1 rs11085226 on glucose-stimulated insulin release in adult Danes.

Tue H Hansen, Henrik Vestergaard, Torben Jørgensen, Marit Eika Jørgensen, Torsten Lauritzen, Ivan Brandslund, Cramer Christensen, Oluf Pedersen, Torben Hansen, Anette P Gjesing

Open access · goldAbstract read
In one paragraph

Article in BMC medical genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. PTBP1 as a potential regulator of disease.Molecular and cellular biochemistry · 2024
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Tue H HansenThe Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, DK-2100, Copenhagen, Denmark. tuehhansen@sund.ku.dk.
Henrik VestergaardThe Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, DK-2100, Copenhagen, Denmark. henrik.vestergaard@sund.ku.dk.
Torben JørgensenResearch Centre for Prevention and Health, Glostrup University Hospital, Nordre Ringvej 57, Building 84-85, DK-2600, Glostrup, Denmark. torben.joergensen@regionh.dk.
Marit Eika JørgensenSteno Diabetes Center, Niels Steensens Vej 2, DK-2820, Gentofte, Denmark. maej@steno.dk.
Torsten LauritzenDepartment of Public Health, Section of General Practice, Aarhus University, Bartholins Allé 2, DK-8000, Aarhus, Denmark. tl@ph.au.dk.
Ivan BrandslundDepartment of Clinical Biochemistry, Vejle Hospital, Kabbeltoft 25, DK-7100, Vejle, Denmark. ivan.brandslund@rsyd.dk.
Cramer ChristensenDepartment of Internal Medicine and Endocrinology, SLB, Vejle Hospital, Kabbeltoft 25, DK-7100, Vejle, Denmark. cramer.kjeldahl.christensen@rsyd.dk.
Oluf PedersenThe Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, DK-2100, Copenhagen, Denmark. oluf@sund.ku.dk.
Torben HansenThe Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, DK-2100, Copenhagen, Denmark. hansen@sund.ku.dk.
Anette P GjesingThe Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 1, DK-2100, Copenhagen, Denmark. anette.gjesing@sund.ku.dk.
Novo Nordisk Foundation · DKUniversity of Copenhagen · DKVejle Sygehus · DKAarhus University · DKGlostrup Hospital · DKSteno Diabetes Center · DKUniversity of Southern Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe variant rs11085226 (G) within the gene encoding polypyrimidine tract binding protein 1 (PTBP1) was reported to associate with reduced insulin release determined by an oral glucose tolerance test (OGTT) as well as an intravenous glucose tolerance test (IVGTT). The aim of the present study was to validate the association of the rs11085226 G-allele of PTBP1 with previously investigated OGTT- and IVGTT-derived diabetes-related metabolic quantitative phenotypes, to conduct exploratory analyses of additional measures of beta-cell function, and to further investigate a potential association with type 2 diabetes.

methodsPTBP1 rs11085226 was genotyped in 20,911 individuals of Danish Caucasian ethnicity ascertained from 9 study samples. Case control analysis was performed on 5,634 type 2 diabetic patients and 11,319 individuals having a normal fasting glucose level as well as 4,641 glucose tolerant controls, respectively. Quantitative trait analyses were performed in up to 13,605 individuals subjected to an OGTT or blood samples obtained after an overnight fast, as well as in 596 individuals subjected to an IVGTT.

resultsAnalyses of fasting and OGTT-derived quantitative traits did not show any significant associations with the PTBP1 rs11085226 variant. Meta-analysis of IVGTT-derived quantitative traits showed a nominally significant association between the variant and reduced beta-cell responsiveness to glucose (β = -0.1 mmol · kg(-1) · min(-1); 95% CI: -0.200.20 - -0.024; P = 0.01) assuming a dominant model of inheritance, but failed to replicate a previously reported association with area under the curve (AUC) for insulin. Case control analysis did not show an association of the PTBP1 rs11085226 variant with type 2 diabetes.

conclusionsDespite failure to replicate the previously reported associations of PTBP1 rs11085226 with OGTT- and IVGTT-derived measures of beta-cell function, we did find a nominally significant association with reduced beta-cell responsiveness to glucose during an IVGTT, a trait not previously investigated, leaving the potential influence of this variant in PTBP1 on glucose stimulated insulin release open for further investigation. However, the present study does not support the hypothesis that the variant confers risk of type 2 diabetes.

Indexed as

Polymorphism, Single NucleotideAdultAllelesCase-Control StudiesDenmarkDiabetes Mellitus, Type 2FastingFemaleGlucoseGlucose Tolerance TestHeterogeneous-Nuclear RibonucleoproteinsHumansInsulinInsulin-Secreting CellsInsulin SecretionMaleGlucoseHeterogeneous-Nuclear RibonucleoproteinsInsulinPolypyrimidine Tract-Binding ProteinPTBP1 protein, human

Identifiers

PMID25927630
PMCPMC4422140
OpenAlexW2043246010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.